The impact of tumor infiltrating lymphocytes (TILs) on disease progression in human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma.

Authors

null

Linda X Yin

Department of Otorhinolaryngology, Mayo Clinic, Rochester, MN

Linda X Yin , Michael Rivera , Joaquin J. Garcia , Kathleen Bartemes , Derrick B Lewis , Christine M. Lohse , David Routman , Daniel Jeng-Lin Ma , Eric J. Moore , Kathryn M. Van Abel

Organizations

Department of Otorhinolaryngology, Mayo Clinic, Rochester, MN, Mayo Clinic Department of Laboratory Medicine and Pathology, Rochester, MN, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, Mayo Clinic Department of Otolaryngology, Rochester, MN, Mayo Clinic Alix School of Medicine, Rochester, MN, Mayo Clinic Department of Health Sciences Research, Rochester, MN, Department of Radiation Oncology, Mayo Clinic, Rochester, MN

Research Funding

No funding received
None

Background: In the head and neck, human papillomavirus-related oropharyngeal squamous cell carcinoma (HPV(+)OPSCC) has a better prognosis and more tumor infiltrating lymphocytes (TILs) compared to its HPV(-) counterpart. Within HPV(+)OPSCC, the prognostic value of TILs in the primary tumor and in metastatic lymph nodes is not well understood. Methods: This is a matched case-control study at a tertiary care center of HPV(+)OPSCC patients who underwent primary surgery between 05/2007–12/2016. Cases developed locoregional recurrence or distant metastases during follow-up, while controls did not during a similar duration of follow-up. Pairs were matched on age, American Joint Committee on Cancer (AJCC) 8th edition pathologic stage, sex, year of surgery, degree of adjuvant treatment, comorbidities, and smoking status. One representative H&E slide of the primary tumor and lymph node (when nodal disease was present) from each patient was independently reviewed by two pathologists (JG, MR) blinded to outcome, for tumor TILs (tTILs) density (defined as % TILs), presence/absence of desmoplastic stroma, and when stroma was present, for stromal TILs (sTILs) density (defined as relative crowding of TILs). The Brandwein-Gensler pattern of invasion (POI) score was used to grade the primary tumor. Interrater agreement was assessed using Cohen’s kappa. Associations between TILs and time to disease progression were assessed using Cox proportional hazards regression models. Results: 41 case-control pairs (N=82) were included in the study: 38 (46%) were AJCC pStage I, 37 (45%) were pStage II, and 7 (9%) were pStage III; 22 (27%) underwent surgery alone, 15 (18%) underwent surgery with adjuvant radiotherapy, and 45 (55%) underwent surgery with adjuvant chemoradiation. Interrater agreement was fair for tTILs density in the primary tumor (k=0.24) and lymph node (k=0.23), moderate for desmoplastic stroma in the primary tumor (k=0.58) and lymph node (k=0.64), moderate for sTILs density in the primary tumor (k=0.58) and lymph node (k=0.48), and fair for the POI score (k=0.17). tTILs density ≥10% (HR 0.35, 95% CI 0.14-0.90, p=0.028) and a moderate/dense sTILs density (HR 0.15, 95% CI 0.04-0.68, p=0.014) in the primary tumor were significantly associated with decreased risk of disease progression. An aggressive POI score of III or IV was significantly associated with increased risk of disease progression (HR 4.00, 95% CI 1.34-11.96, p=0.013). None of the study measures in the lymph node were significantly associated with disease progression. Conclusions: In HPV(+)OPSCC, a higher density of tumor and stromal TILs and nonaggressive POI in the primary tumor specimen may indicate a lower risk of disease progression. TILs may serve as a powerful prognostic marker for the adaptive immune response to this disease.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 6049)

DOI

10.1200/JCO.2021.39.15_suppl.6049

Abstract #

6049

Poster Bd #

Online Only

Abstract Disclosures